CoChat

Ertugliflozin in Patients with Stage 3 Chronic Kidney Disease and Type 2 Diabetes Mellitus: The VERTIS RENAL Randomized Study

Open access
Grunberger, George, Camp, Sarah, Johnson, Jeremy, Huyck, Susan, Terra, Steven G., Mancuso, James P., Jiang, Zhi Wei, Golm, Gregory, Engel, Samuel S., Lauring, Brett · 2018 · Diabetes Therapy
Cited by 148

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

Ertugliflozin is a sodium-glucose cotransporter 2 inhibitor in development for type 2 diabetes mellitus (T2DM). The safety and efficacy of ertugliflozin were evaluated over 52 weeks in patients with chronic kidney disease (CKD). In this double-blind randomized study (NCT01986855), patients with glycated hemoglobin (A1C) 7.0–10.5% and stage 3 CKD [estimated glomerular filtration rate (eGFR) ≥ 30 to < 60 mL/min/1.73 m 2 ] who were undergoing treatment with standard diabetes therapy (or therapies) including insulin and/or sulfonylureas were randomized to once-daily ertugliflozin 5 mg, 15 mg, or placebo. Patients on metformin underwent a pre-randomization ≥ 10-week wash-off period. The primary endpoint was change from baseline in A1C at week 26 in the overall cohort. Secondary efficacy endpoints were assessed in the stage 3A CKD cohort (eGFR ≥ 45 to < 60 mL/min/1.73 m 2 ) at weeks 26 and 52. Safety was assessed in the overall cohort. 468 patients were randomized (baseline mean A1C 8.2%). At week 26, reductions from baseline in A1C were observed across groups in the overall cohort [least squares mean changes (95% confidence interval) – 0.3% (– 0.4, – 0.1), – 0.3% (– 0.4, – 0.1), and – 0.4% (– 0.6, – 0.3) for placebo and for ertugliflozin 5 mg and 15 mg, respectively]. Prohibited use of metformin was identified in ~ 17% of patients and impacted evaluation of the primary endpoint. Greater reductions from baseline in body weight, fasting plasma glucose, and systolic blood pressure were observed with ertugliflozin versus placebo at week 26 (stage 3A CKD cohort). The incidences of urinary tract infections, genital mycotic infections, and hypoglycemia adverse events were not meaningfully different between groups. The incidence of hypovolemia-related adverse events was higher with ertugliflozin relative to placebo. Although surreptitious metformin use impacted the primary analysis, reductions in blood glucose and body weight were observed with ertugliflozin in patients with T2DM and stage 3 CKD; ertugliflozin had an acceptable safety profile. Merck Sharp & Dohme Corp. a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA and Pfizer Inc. Clinicaltrials.gov identifier NCT01986855.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s13300-017-0337-5

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 15

  1. Dandona P, Chaudhuri A. Sodium-glucose co-transporter 2 inhibitors for type 2 diabetes mellitus: an overview for the primary care physician. Int J Clin Pract. 2017;71:e12937. · DOI
  2. Scheen AJ. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus. Drugs. 2015;75:33–59. · DOI · Paper page
  3. Fioretto P, Zambon A, Rossato M, Busetto L, Vettor R. SGLT2 inhibitors and the diabetic kidney. Diabetes Care. 2016;39(Suppl 2):S165–71. · DOI · Paper page
  4. Barnett AH, Mithal A, Manassie J, Jones R, Rattunde H, Woerle HJ, et al. Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2014;2:369–84. · DOI · Paper page
  5. Yale JF, Bakris G, Cariou B, Yue D, David-Neto E, Xi L, et al. Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab. 2013;15:463–73. · DOI · Paper page
  6. Mascitti V, Maurer TS, Robinson RP, Bian J, Boustany-Kari CM, Brandt T, et al. Discovery of a clinical candidate from the structurally unique dioxa-bicyclo[3.2.1]octane class of sodium-dependent glucose cotransporter 2 inhibitors. J Med Chem. 2011;54:2952–60. · DOI · Paper page
  7. American Diabetes Association. Executive summary: standards of medical care in diabetes—2012. Diabetes Care. 2012;35(Suppl 1):S4–10. · DOI · Paper page
  8. Liang K-Y, Zeger SL. Longitudinal data analysis of continuous and discrete responses for pre-post designs. Sankhya Ser B. 2000;62:134–48.
  9. Miettinen O, Nurminen M. Comparative analysis of two rates. Stat Med. 1985;4:213–26. · DOI · Paper page
  10. Gantz I, Sokolova L, Jain L, Iredale C, O’Neill E, Wei Z, et al. Use of prohibited medication, a potentially overlooked confounder in clinical trials: randomized omarigliptin (once-weekly DPP-4 inhibitor) monotherapy trial in 18–45 year-olds. Clin Ther. 2017;9:2024–37. · doi:10.1016/j.clinthera.2017.08.009
  11. Sahasrabudhe V, Terra S, Fountaine R, Hickman A, Saur D, Matschke K, et al. The effect of renal impairment on the pharmacokinetics and pharmacodynamics of ertugliflozin in subjects with type 2 diabetes mellitus. J Clin Pharmacol 2017;57:1432–43. · DOI
  12. Kadokura T, Zhang W, Krauwinkel W, Leeflang S, Keirns J, Taniuchi Y, et al. Clinical pharmacokinetics and pharmacodynamics of the novel SGLT2 inhibitor ipragliflozin. Clin Pharmacokinet. 2014;53:975–88. · DOI
  13. Macha S, Mattheus M, Halabi A, Pinnetti S, Woerle HJ, Broedl UC. Pharmacokinetics, pharmacodynamics and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in subjects with renal impairment. Diabetes Obes Metab. 2014;16:215–22. · DOI · Paper page
  14. Terra SG, Focht K, Davies M, Frias J, Derosa G, Darekar A, et al. Phase III, efficacy and safety study of ertugliflozin monotherapy in people with type 2 diabetes mellitus inadequately controlled with diet and exercise alone. Diabetes Obes Metab. 2017;19:721–8. · DOI · Paper page
  15. Yamout H, Perkovic V, Davies M, Woo V, de Zeeuw D, Mayer C, et al. Efficacy and safety of canagliflozin in patients with type 2 diabetes and stage 3 nephropathy. Am J Nephrol. 2014;40:64–74. · DOI · Paper page

Cited by

See all 148

Metadata

Authors
Grunberger, G., Camp, S., Johnson, J., Huyck, S., Terra, S. G., Mancuso, J. P., Jiang, Z. W., Golm, G., Engel, S. S., & Lauring, B.
Venue
Diabetes Therapy
Published
2017-11-20
Volume
9
Issue
1
Pages
49-66
ISSN
  • 1869-6953 (ISSN-L)
  • 1869-6961
OpenAlex
W2769581384
Cited by
148
References
6
FWCI
10.39
Type
journal article
Language
en
Open access
gold
Funders
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA, in collaboration with Pfizer Inc, provided financial support for this study.

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.